Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models

PUJATTI, PRISCILLA B.FOSTER, JULIE M.FINUCANE, CIARAHUDSON, CHANTELLE D.BURNET, JEROME C.PASQUALOTO, KERLY F.M.MENGATTI, JAIRMATHER, STEPHEN J.ARAUJO, ELAINE B. deSOSABOWSKI, JANE K.2015-01-062015-01-062015PUJATTI, PRISCILLA B.; FOSTER, JULIE M.; FINUCANE, CIARA; HUDSON, CHANTELLE D.; BURNET, JEROME C.; PASQUALOTO, KERLY F.M.; MENGATTI, JAIR; MATHER, STEPHEN J.; ARAUJO, ELAINE B. de; SOSABOWSKI, JANE K. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models. <b>Applied Radiation and Isotopes</b>, v. 96, p. 91-101, 2015. DOI: <a href="https://dx.doi.org/10.1016/j.apradiso.2014.11.006">10.1016/j.apradiso.2014.11.006</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/23226.0969-8043http://repositorio.ipen.br/handle/123456789/23226We evaluated and compared a new bombesin analog [Tyr–Gly5, Nle14]-BBN(6–14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTApeptide to PC-3 cells was observed. Both peptides could91-101openAccessradiopharmaceuticalsdtpalabelled compoundsindium 111neoplasmspeptidesimpuritiescomparative evaluationsEvaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor modelsArtigo de periódico9610.1016/j.apradiso.2014.11.006https://orcid.org/0000-0003-0456-558935.56